Insilico Medicine
United States, Boston, Massachusetts
About Insilico Medicine
Insilico Medicine is a clinical-stage company that uses generative artificial intelligence to drive drug discovery, combining AI platform licensing with internal drug development programs.
Latest Funding
Series C+Announced 2025-06-16
Buying Signals
Where the capital is going, and whether it's already started moving.
Spend Intent
2 signals · where the capital is going
Commercialize generative AI platform for pharmaceutical drug development
biopharmatrend.com
+1 more capital deployment signal · confidence ratings · source articles
Sign up freeHiring Signals
3 open roles · capital meeting headcount
R&D spend backed by 2 engineering hires, product build in motion
Roles across United Arab Emirates, open globally (Preferred: Japan, Europe)
+1 more hiring signal · full department matrix · role-by-role drill-down
Sign up freeTop hiring departments
In the news
Selling to Insilico Medicine? You're in the right place.
Knowing they raised is the start. The edge is what's attached to Insilico Medicine.
Spend intent
Where this round will be spent.
Hiring signals
Which departments are growing.
Verified contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Ask AI
What is the unique value proposition of Insilico Medicine, and who are their main competitors?
Sign up free to ask AI about Insilico Medicine
Our AI has read their website, news, and funding history. 25 credits included with every free account.
Sign up free: 25 credits includedAuto-matched to your ICP
Every company, scored against your profile. Automatically.
Industry
High
Size
Mid
Stage
High
Match score blends industry, company size, growth stage, tech stack, and geography. The moment you set your ICP, every company in our database gets scored.
Investors
Prosperity7 Ventures
Lead investor · Series C+
Tech Stack
Hammer.js
DDoS-Guard
Tilda
Key Highlights
AI InsightsThe company has a portfolio of over 30 programs, with 10 having received IND clearance, including rentosertib (ISM001-055) in Phase IIa trials for idiopathic pulmonary fibrosis and ISM6331 in early-stage solid tumor trials in the U.S. and China.
AI reads their website, press releases, and funding context to surface what makes them unique - so you tailor your pitch before the first call.
Try it free →Generates a personalized cold email based on their funding round, capital deployment signals, and company context. Ready to send in under 10 seconds.
Try it free →Short, personalized connection request crafted around their recent funding and what your product can help them achieve with it.
Try it free →Maps their competitive landscape with AI - invaluable context before your first call and for positioning your pitch against their alternatives.
Try it free →Extracts capital deployment signals from their funding news - reach out knowing exactly where they're investing and why your product fits.
Try it free →Similar Companies
Discover companies similar to Insilico Medicine
Selling to Insilico Medicine? You're in the right place.
Knowing they raised is the start. Our difference is what comes attached to Insilico Medicine.
Spend Intent
Where this round will be spent.
Hiring Signals
Which departments are growing.
Verified Contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Free weekly newsletter on startup funding.
20 rounds, ranked by amount. Industry and stage breakdowns. A short market note. One email, free, no noise. 2,000+ subscribers.
No spam, ever. Unsubscribe with one click.